Administration Expands Access to Unapproved Peptide Supplements Amid Agency Pushback
The Trump administration, under Health Secretary Robert F. Kennedy Jr., issued a policy directing the FDA not to act against specialty pharmacies selling six unapproved wellness peptides. FDA scientists opposed the move, warning it could compromise safety standards and undermine regulatory oversight. The decision is expected to boost the market for these unproven substances, which are promoted for muscle growth and recovery despite lacking clinical validation.
On October 28, 2026, the Trump administration, under Health Secretary Robert F. Kennedy Jr., issued a directive instructing the FDA not to take enforcement action against specialty pharmacies selling six unapproved wellness peptides—BPC-157, TB-500, and KPV among them—despite strong opposition from FDA scientific staff. These substances, which lack FDA approval for safety or efficacy, are marketed for muscle growth, injury recovery, and other medical-sounding benefits without clinical validation. The policy shift, posted by the Department of Health and Human Services (HHS), represents a significant departure from decades of FDA efforts to restrict unproven therapies, particularly those sold online with questionable sourcing. While HHS claims the move offers a safer alternative to black-market peptides by channeling sales through licensed U.S. compounders, critics argue it undermines regulatory integrity. The FDA’s scientific staff had raised serious safety concerns and refused to support formal regulations deeming these peptides safe for compounding, leading HHS to bypass rulemaking and instead issue a non-enforcement directive.
Kennedy, a vocal advocate of alternative medicine and leader of the “Make America Healthy Again” (MAHA) movement, has publicly endorsed these peptides, including using BPC-157 to treat personal injuries. His administration’s decision aligns with broader MAHA goals of expanding access to unproven treatments, drawing support from wellness entrepreneurs
This policy shift could significantly expand access to unproven medical substances, potentially increasing consumer exposure to products with unknown long-term risks. Patients seeking alternatives to conventional treatments—especially those disillusioned with traditional medicine—may be drawn to these peptides, particularly if promoted by popular telehealth platforms. The move may also incentivize further investment in the wellness peptide market, accelerating commercialization of unregulated compounds. However, this could erode trust in regulatory agencies, especially if adverse events emerge without clear oversight. A comparable precedent is the 2012 fungal meningitis outbreak linked to contaminated compounded drugs, which led to stricter FDA enforcement. That case underscores how lax oversight can result in public health crises. The current situation may test whether non-enforcement directives can be effectively monitored or if they will become a backdoor for unregulated medical pro